Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
10x Genomics (TXG) announced the launch of the Fixed RNA Profiling Kit and Nuclei Isolation Kit on April 14, 2022. These products enhance sample preparation workflows for single cell analysis, targeting the challenges in handling fragile human tissues and frozen samples. The Fixed RNA Profiling Kit allows researchers to store samples post-collection without cryopreservation, while the Nuclei Isolation Kit simplifies the extraction of nuclei from frozen tissue, making the process more efficient. Both kits are set to ship mid-May 2022, aiming to broaden the use of single cell analysis in research.
10x Genomics (Nasdaq: TXG) will report its financial results for Q1 2022 after market close on May 4, 2022. A conference call to discuss these results, along with business developments and future outlook, will begin at 1:30 p.m. PT / 4:30 p.m. ET. The live audio of the webcast will be accessible through the company's website and archived for 45 days. 10x Genomics focuses on life science technology advancements, with significant adoption in top global research institutions and pharmaceutical companies.
10x Genomics (Nasdaq: TXG) will participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 12:50 p.m. ET. The company's management will engage in a virtual fireside chat to discuss business activities. Interested parties can access the live and archived webcast through the company's website.
Recognized for advancing human health, 10x Genomics provides integrated solutions for biological analysis, widely used by premier research institutions and pharmaceutical companies globally.
10x Genomics (Nasdaq: TXG) announced new product details at its Xperience 2022 virtual event, showcasing innovations in single cell and spatial analysis technologies. Key products include the Chromium Fixed RNA Profiling Kit for improved sample preparation, Visium CytAssist to enhance spatial analysis capabilities, and a preview of the Xenium Analyzer, targeting gene expression at subcellular resolution. The company emphasizes its commitment to advancing human health through groundbreaking technologies, with multiple product launches planned for 2022.
10x Genomics, Inc. (Nasdaq: TXG) reported strong financial results for Q4 and full year 2021, with revenues of $143.5 million for Q4 and $490.5 million for the year, reflecting increases of 28% and 64%, respectively, compared to 2020. Gross margins for Q4 were 81%, slightly down from 83% year-over-year. Significant operating losses decreased to $15.8 million in Q4 from $409.6 million a year earlier. For 2022, the company projects revenues of $600 million to $630 million, indicating 22% to 28% growth.
10x Genomics (Nasdaq: TXG) will release its fourth quarter and full year financial results for 2021 on February 16, 2022. A conference call is scheduled at 1:30 p.m. PT to discuss the results and future outlook. The company's integrated solutions for biological analysis have been widely adopted globally, with significant citations in research. 10x Genomics holds a robust patent portfolio exceeding 1,300 patents.
10x Genomics (Nasdaq: TXG) expanded its 10x Certified Service Provider Network by adding three clinical research organizations: Q2 Solutions, Azenta Life Sciences, and CellCarta. This initiative aims to assist global biopharmaceutical companies in utilizing its advanced single-cell and spatial technologies for drug development. The partnership is designed to help predict therapy resistance in cancer patients and enhance clinical trial outcomes. Established in 2018, the program now includes over 40 service providers worldwide, showcasing an increasing demand for innovative genomic solutions.
ReCode Therapeutics announced the appointment of Shehnaaz Suliman as CEO and board member, effective immediately. Former CEO David Lockhart transitions to Chief Scientific Officer. Dr. Suliman, with over 25 years in drug development, previously led Alector and held key roles at Theravance and Roche. She aims to advance ReCode's pipeline of genetic medicines utilizing their selective organ targeting platform. The leadership change is anticipated to enhance growth and innovative therapeutics in the biopharmaceutical space.
10x Genomics (Nasdaq: TXG) announced participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET. The presentation will be accessible via a live and archived webcast on the company's website. 10x Genomics specializes in life science technology, offering integrated solutions for biological analysis.
Its products are utilized globally, including by top research institutions and pharmaceutical companies. The company boasts over 1,200 patents and has contributed to significant research in areas like oncology and neuroscience.
Summary not available.